38 terminated. 38 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 38 | Terminated 38 |
| Phase 2 | 7 | Terminated 7 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD) - Multiple Myeloma | Phase 3 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 28 | 2023-03-03 | 2026-01-05 |
| Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma Melflufen, Dexamethasone, Daratumumab - Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma | Phase 3 | Terminated | Oncopeptides AB | 54 | 2020-12-21 | 2023-06-08 |
| Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin Belantamab mafodotin - Multiple Myeloma | Phase 3 | Terminated | GlaxoSmithKline | 16 | 2020-12-21 | 2023-12-13 |
| Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients Propranolol treatment, Placebo - Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease | Phase 3 | Terminated | University Hospital, Bordeaux | 15 | 2020-06-23 | 2026-06-23 |
| Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis Colchicine - IgA Vasculitis | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 27 | 2019-11-12 | 2026-11-06 |
| Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis Rivaroxaban 15 mg, Warfarin - Prostheses and Implants, Stroke | Phase 2 / Phase 3 | Terminated | Hospital Geral Roberto Santos | 50 | 2018-07-10 | 2020-05-15 |
| A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide Melflufen, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Oncopeptides AB | 495 | 2017-06-12 | 2024-01-30 |
| Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment Pomalidomide, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Fondazione EMN Italy Onlus | 9 | 2016-02-18 | 2021-03-10 |
| BiRd vs. Rd as Initial Therapy in Multiple Myeloma Clarithromycin, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Weill Medical College of Cornell University | 12 | 2016-02-01 | 2023-06-05 |
| Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) Pembrolizumab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 251 | 2015-10-19 | 2021-10-08 |
| Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) Pembrolizumab, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 310 | 2015-10-19 | 2021-07-20 |
| Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Bevacizumab, placebo - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2 / Phase 3 | Terminated | Hospices Civils de Lyon | 80 | 2014-04-01 | 2015-11-20 |
| Treatment Optimization in Patients With Untreated Multiple Myeloma Lenalidomide, Placebo - Multiple Myeloma | Phase 2 / Phase 3 | Terminated | Dr. med. Lars-Olof Muegge | 85 | 2013-08-01 | 2019-01-16 |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Placebo, Rituximab, Idelalisib - Indolent Non-Hodgkin's Lymphomas | Phase 3 | Terminated | Gilead Sciences | 295 | 2013-01-16 | 2018-11-16 |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Idelalisib, Rituximab, Bendamustine - Indolent Non-Hodgkin's Lymphomas | Phase 3 | Terminated | Gilead Sciences | 475 | 2013-01-02 | 2018-11-16 |
| RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate, Fresh Frozen Plasma blood type 0, A, B and AB - Major Trauma | Phase 3 | Terminated | Medical University Innsbruck | 100 | 2012-03-01 | 2016-03-23 |
| Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide plerixafor, filgrastim - Refractory Multiple Myeloma | Phase 3 | Terminated | Case Comprehensive Cancer Center | 9 | 2011-07-01 | 2014-08-06 |
| A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma Masitinib, Placebo, Bortezomib - Multiple Myeloma | Phase 3 | Terminated | AB Science | 147 | 2011-05-01 | 2018-12-19 |
| Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients Perifosine, Perifosine Placebo, Bortezomib - Multiple Myeloma | Phase 3 | Terminated | AEterna Zentaris | 135 | 2009-12-01 | 2018-02-09 |
| Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients velcade - Multiple Myeloma | Phase 2 / Phase 3 | Terminated | Shanghai Jiao Tong University School of Medicine | 23 | 2009-08-01 | 2016-09-08 |
Showing 20 of 38. Sign in to see all of them.
Multiple Myeloma (28) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Myeloproliferative Disorders (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Blast Crisis (2) · Breast Neoplasms (2) · Burkitt Lymphoma (2) · Carcinoma, Ovarian Epithelial (2) · Epistaxis (2) · Graft vs Host Disease (2)
Cardiovascular Diseases (38) · Hemic and Lymphatic Diseases (38) · Hemorrhagic Disorders (38) · Vascular Diseases (38) · Hematologic Diseases (37) · Blood Protein Disorders (31) · Immune System Diseases (31) · Immunoproliferative Disorders (30) · Lymphoproliferative Disorders (30) · Neoplasms by Histologic Type (30) · Paraproteinemias (30) · Neoplasms (29) · Neoplasms, Plasma Cell (29) · Pathological Conditions, Signs and Symptoms (12)
Dexamethasone (13) · Bortezomib (8) · Calcium Dobesilate (5) · Thalidomide (5) · Lenalidomide (4) · pomalidomide (4) · Zoledronic Acid (3) · Cyclophosphamide (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · L-melphalanyl-p-L-fluorophenylalanine ethyl ester (2) · Melphalan (2) · Rituximab (2) · daratumumab (2) · dexamethasone acetate (2)
University of Arkansas (3) · Gilead Sciences (2) · Merck Sharp & Dohme LLC (2) · Oncopeptides AB (2) · AB Science (1) · AEterna Zentaris (1) · Assistance Publique - Hôpitaux de Paris (1) · Case Comprehensive Cancer Center (1) · Central Hospital, Nancy, France (1) · Dr. med. Lars-Olof Muegge (1) · European Society for Blood and Marrow Transplantation (1) · Fondazione EMN Italy Onlus (1) · GlaxoSmithKline (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hoffmann-La Roche (1)
United States (20) · France (9) · Germany (9) · Czechia (6) · Italy (6) · Canada (5) · Israel (5) · Russia (5) · Spain (5) · United Kingdom (5) · Poland (4) · South Korea (4) · Austria (3) · Belgium (3) · Hungary (3)
Bart Barlogie, MD, PhD (2) · Andre Duraes, PhD (1) · Andrea Velardi, MD (1) · Annamaria Brioli, MD (1) · Bertrand Arnulf, MD (1) · Cyrille Hulin, MD (1) · Denis-Claude Roy, MD (1) · Francis Ayuk, Prof. Dr. med. (1) · Frits van Rhee, MD, PhD (1)
PMID 19270260, PMID 22674807, PMID 27599328, PMID 28457980, PMID 30293126, PMID 31327687, PMID 31327689, PMID 33086159, PMID 33150497, PMID 35032434, PMID 37355418, PMID 37646657, PMID 37646660, PMID 38426292, PMID 39865222, PMID 40338596, PMID 41437395
2015 (2), 2005 (1), 2016 (1), 2018 (1), 2019 (1), P30CA069533 (1), U10CA021115 (1), U10CA032102 (1), U10CA180820 (1)